{"id":"https://openalex.org/W4292012417","doi":null,"title":"Dasatinib: BMS 354825.","display_name":"Dasatinib: BMS 354825.","alternate_titles":[],"publication_year":2006,"publication_date":"2006-01-01","ids":{"openalex":"https://openalex.org/W4292012417","pmid":"https://pubmed.ncbi.nlm.nih.gov/16542059"},"language":"en","primary_location":{"id":"pmid:16542059","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16542059","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs in R&D","raw_type":"Journal Article"},"parent_works":[],"lineage":["https://openalex.org/W4292012417"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"7","issue":"2","first_page":"129","last_page":"132"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":1.0},{"id":"https://openalex.org/keywords/src-inhibitors","display_name":"Src kinase inhibitor","score":0.6570000052452087},{"id":"https://openalex.org/keywords/abl-kinase-inhibitors","display_name":"ABL kinase inhibitors","score":0.9869999885559082},{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.8849999904632568},{"id":"https://openalex.org/keywords/imatinib-resistance","display_name":"imatinib resistance","score":0.9869999885559082},{"id":"https://openalex.org/keywords/imatinib-intolerance","display_name":"imatinib intolerance","score":0.8069999814033508},{"id":"https://openalex.org/keywords/philadelphia-chromosome-positive-acute-lymphoblastic-leukemia","display_name":"Philadelphia chromosome-positive acute lymphoblastic leukemia","score":0.8980000019073486},{"id":"https://openalex.org/keywords/multidrug-resistance","display_name":"multidrug resistance","score":0.7020000219345093},{"id":"https://openalex.org/keywords/bcr-abl-mutations","display_name":"BCR-ABL mutations","score":0.8169999718666077},{"id":"https://openalex.org/keywords/lyn-kinase","display_name":"Lyn kinase","score":0.7570000290870667},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.7839999794960022},{"id":"https://openalex.org/keywords/oral-anticancer-drugs","display_name":"oral anticancer drugs","score":0.5789999961853027},{"id":"https://openalex.org/keywords/drug-development","display_name":"drug development","score":0.47600001096725464}],"concepts":[{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.9842061996459961},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.7631160616874695},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7208192944526672},{"id":"https://openalex.org/C2776960273","wikidata":"https://www.wikidata.org/wiki/Q729735","display_name":"Chronic myelogenous leukemia","level":3,"score":0.646804928779602},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5545865893363953},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5184647440910339},{"id":"https://openalex.org/C2777413986","wikidata":"https://www.wikidata.org/wiki/Q412327","display_name":"Nilotinib","level":4,"score":0.4792461395263672},{"id":"https://openalex.org/C125418893","wikidata":"https://www.wikidata.org/wiki/Q587961","display_name":"ABL","level":4,"score":0.4584578573703766},{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.42136555910110474},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.39646583795547485},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.34089842438697815},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.2888297438621521},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.2862696051597595},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.22490352392196655},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.07041051983833313}],"mesh":[{"descriptor_ui":"D000069439","descriptor_name":"Dasatinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011505","descriptor_name":"Protein-Tyrosine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D011505","descriptor_name":"Protein-Tyrosine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016044","descriptor_name":"Fusion Proteins, bcr-abl","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017321","descriptor_name":"Clinical Trials, Phase I as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":1,"locations":[{"id":"pmid:16542059","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16542059","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs in R&D","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2578703009","https://openalex.org/W2582021609","https://openalex.org/W2094615952","https://openalex.org/W2575086792","https://openalex.org/W4256391755","https://openalex.org/W2333888998","https://openalex.org/W2121990442","https://openalex.org/W2560411042","https://openalex.org/W200163820","https://openalex.org/W2112405804"],"abstract_inverted_index":{"Dasatinib":[0,234],"[BMS":[1],"354825]":[2],"is":[3,18,85,235],"an":[4],"orally":[5,220],"active,":[6],"small":[7],"molecule,":[8],"dual":[9],"inhibitor":[10],"of":[11,27,67,73,78,82,90,97,127,201,226],"both":[12],"SRC":[13],"and":[14,34,71,95,182,192,228],"ABL":[15],"kinases":[16],"that":[17,110,166,259],"under":[19],"development":[20],"with":[21,29,46,87,147,214,224],"Bristol-Myers":[22,107,156,249],"Squibb":[23,108,157,250],"for":[24,43,122,240],"the":[25,74,79,91,114,119,125,155,163,187,199],"treatment":[26,126],"patients":[28,45,146],"chronic":[30],"myelogenous":[31],"leukaemia":[32,143],"(CML)":[33],"imatinib-acquired":[35,83],"resistance/intolerance.":[36],"While":[37],"imatinib":[38,53],"remains":[39],"a":[40,244,252],"frontline":[41],"therapy":[42,54,245],"CML,":[44],"advanced":[47],"disease":[48],"frequently":[49],"develop":[50],"resistance":[51,84,148],"to":[52,118,151,169],"through":[55],"multiple":[56,247],"mechanisms.":[57],"These":[58],"mechanisms":[59],"include":[60],"insufficient":[61],"potency":[62],"at":[63],"therapeutic":[64],"doses,":[65],"activation":[66],"alternate":[68],"oncogenic":[69],"pathways,":[70],"overexpression":[72],"multidrug-resistant":[75],"gene.":[76],"One":[77],"possible":[80],"causes":[81],"associated":[86],"increased":[88],"expression":[89],"SRC-related":[92],"kinase":[93],"Lyn":[94],"loss":[96],"BCR-ABL":[98],"dependence":[99],"arising":[100],"from":[101],"sequence":[102],"mutations.":[103],"In":[104,175,208],"December":[105],"2005,":[106,162],"announced":[109],"it":[111,167],"has":[112,211,251],"completed":[113],"rolling":[115],"NDA":[116],"submission":[117],"US":[120],"FDA":[121],"dasatinib":[123,171,179,210],"in":[124,129,145,160,172,176,186,221,262],"CML":[128,193,231],"chronic,":[130],"accelerated":[131],"or":[132,149],"blast":[133],"phases,":[134],"as":[135,137,243],"well":[136],"Philadelphia":[138],"chromosome-positive":[139],"(Ph+)":[140],"acute":[141],"lymphoblastic":[142],"(ALL)":[144],"intolerance":[150],"prior":[152],"treatment.":[153],"At":[154],"R&D":[158],"Day":[159],"May":[161],"company":[164],"stated":[165],"plans":[168],"evaluate":[170],"solid":[173],"tumours.":[174],"vitro":[177],"assays,":[178],"induced":[180],"apoptosis":[181],"had":[183],"potent":[184],"activity":[185],"imatinib-resistant":[188,206],"tumour":[189],"cells":[190,202,232],"lines":[191],"patient":[194],"specimens.":[195],"It":[196],"effectively":[197],"inhibited":[198],"proliferation":[200],"expressing":[203],"nearly":[204],"all":[205],"isoforms.":[207],"vivo,":[209],"shown":[212],"efficacy,":[213],"no":[215],"apparent":[216],"toxicity,":[217],"when":[218],"administered":[219],"SCID":[222],"mice":[223],"xenografts":[225],"imatinib-sensitive":[227],"resistant":[229],"human":[230],"lines.":[233],"also":[236],"undergoing":[237],"preclinical":[238],"evaluation":[239],"its":[241],"potential":[242],"against":[246],"myeloma.":[248],"composition-of-matter":[253],"patent":[254],"covering":[255],"this":[256],"research":[257],"approach":[258],"will":[260],"expire":[261],"2020.":[263]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4292012417","counts_by_year":[],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2022-08-17T00:00:00"}
